Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder among women of reproductive age. PCOS is characterized by ovulatory dysfunction, clinical or biochemical features of hyperandrogenism, and polycystic ovaries. The risk of cancer among PCOS patients has been a topic of discussion for decades due to the overlapping metabolic and endocrine abnormalities. This review article focuses on the association of PCOS with various types of reproductive (such as endometrial cancer, ovarian cancer, and breast cancer) and non-reproductive cancers, considering different aspects, such as the risk of cancer progression in PCOS patients, the underlying factors, and the mechanism through which PCOS might progress to cancer. The information provided in this article would help create awareness among PCOS patients about the need to take risk-reducing measures. This article might also aid in the effort of identifying novel therapeutic targets to counteract the progression of cancer in PCOS.

Shermin S, Noor A, Jahan S, 2019, Polycystic ovary syndrome: A brief review with recent updates. Delta Med Coll J, 7(2): 84–99. https://doi.org/10.3329/dmcj.v7i2.45567

Hasan M, Sultana S, Sohan M, et al., 2022, Prevalence and associated risk factors for mental health problems among patients with polycystic ovary syndrome in Bangladesh: A nationwide cross-sectional study. PLoS One, 17(6): e0270102. https://10.1371/journal.pone.0270102

Guzick DS, 2004, Polycystic ovary syndrome. Obstet Gynecol, 103(1): 181–193. https://doi.org/10.1097/01.AOG.0000104485.44999.C6

Lim JJ, Lima PD, Salehi R, et al., 2017, Regulation of androgen receptor signaling by ubiquitination during folliculogenesis and its possible dysregulation in polycystic ovarian syndrome. Sci Rep, 7(1): 10272. https://doi.org/10.1038/s41598-017-09880-0

Ruan X, Kubba A, Aguilar A, et al., 2017, Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: Rationale and practical aspects. Eur J Contracept Reprod Health Care, 22(3): 183–190. https://doi.org/10.1080/13625187.2017.1317735

Kamrul-Hasan AB, Aalpona FT, Mustari M, et al., 2020, Divergences in clinical, anthropometric, metabolic, and hormonal parameters among different phenotypes of polycystic ovary syndrome presenting at endocrinology outpatient departments: A multicenter study from Bangladesh. J Hum Reprod Sci, 13(4): 277–284. https://doi.org/10.4103/jhrs.JHRS_34_20

Fauser BC, Tarlatzis BC, Rebar RW, et al., 2012, Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3^rd PCOS Consensus workshop Group. Fertil Steril, 97(1): 28–38.e25. https://doi.org/10.1016/j.fertnstert.2011.09.024

Corbould A, Kim YB, Youngren JF, et al., 2005, Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab, 288(5): E1047–E1054. https://doi.org/10.1152/ajpendo.00361.2004

Balen A, 2001, Polycystic ovary syndrome and cancer. Hum Reprod Update, 7(6): 522–525. https://doi.org/10.1093/humupd/7.6.522

Siegel RL, Miller KD, Jemal A, 2016, Cancer statistics, 2016. CA Cancer J Clin, 66(1): 7–30. https://doi.org/10.3322/caac.21332

Stein IF, Leventhal ML, 1935, Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol, 29(2): 181–191. https://doi.org/10.1016/S0002-9378(15)30642-6

Speert H, 1949, Carcinoma of the endometrium in young women. Surg Gynecol Obstet, 88(3): 332–336.

Harris HR, Terry KL, 2016, Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: A systematic review. Fertil Res Pract, 2(1): 1–9. https://doi.org/10.1186/s40738-016-0029-2

Cirillo PM, Wang ET, Cedars MI, et al., 2016, Irregular menses predicts ovarian cancer: Prospective evidence from the child health and development studies. Int J Cancer, 139(5): 1009–1017. https://doi.org/10.1002/ijc.30144

Li Y, Chen C, Ma Y, et al., 2019, Multi-system reproductive metabolic disorder: Signifcance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci, 228: 167–175. https://doi.org/10.1016/j.lfs.2019.04.046

Gadducci A, Gargini A, Palla E, et al., 2005, Polycystic ovary syndrome and gynecological cancers: Is there a link? J Gynaecol Endocrinol, 20(4): 200–208. https://doi.org/10.1080/09513590400021201

Syed V, Ulinski G, Mok SC, et al., 2001, Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res, 61(18): 6768–6776.

Modugno F, 2004, Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: A HuGE review. Am J Epidemiol, 159(4): 319–335. https://doi.org/10.1093/aje/kwh046

Ding DC, Chen W, Wang JH, et al., 2018, Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: A population-based cohort study in Taiwan. Medicine (Baltimore), 97(39): e12608. https://doi.org/10.1097/MD.0000000000012608

Beral V, Doll R, Hermon C, et al., 2008, Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, 371(9609): 303–314. https://doi.org/10.1016/S0140-6736(08)60167-1

Anderson KE, Sellers TA, Chen PL, et al., 1997, Association of Stein Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer, 79(3): 494–499.

Shobeiri F, Jenabi E, 2016, The association between polycystic ovary syndrome and breast cancer: A meta-analysis. Obstet Gynecol Sci, 59(5): 367–372. https://doi.org/10.5468/ogs.2016.59.5.367

Fanta M, 2013, Is polycystic ovary syndrome, a state of relative estrogen excess, a real risk factor for estrogen-dependant malignancies? Gynecol Endocrinol, 29(2): 145–147. https://doi.org/10.3109/09513590.2012.730575

Urbanek M, Legro Driscoll DA, et al., 1999, Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A, 96(15): 8573–8578. https://doi.org/10.1073/pnas.96.15.8573

Liu Y, Gold EB, Lasley BL, et al., 2004, Factors affecting menstrual cycle characteristics. Am J Epidemiol, 160(2): 131–140. https://doi.org/10.1093/aje/kwh188

Rani R, Hajam YA, Kumar R, et al., 2022, A landscape analysis of the potential role of polyphenols for the treatment of Polycystic Ovarian Syndrome (PCOS). Phytomed Plus, 2(1): 100161. https://doi.org/10.1016/j.phyplu.2021.100161

Bulsara J, Patel P, Soni A, et al., 2021, A review: Brief insight into polycystic ovarian syndrome. Endocrinol Metab Sci, 3: 100085. https://doi.org/10.1016/j.endmts.2021.100085

Ibáñez L, Oberfield SE, Witchel S, et al., 2017, An international consortium update: Pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr, 88(6): 371–395. https://doi.org/10.1159/000479371

Dumesic DA, Oberfield SE, Stener-Victorin E, et al., 2015, Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev, 36(5): 487–525. https://doi.org/10.1159/000479371

Kanbour SA, Dobs AS, 2022, Hyperandrogenism in women with polycystic ovarian syndrome: Pathophysiology and controversies. Androgens Clin Res Ther, 3(1): 22–30. https://doi.org/10.1089/andro.2021.0020

Cheung AP, Cog F, 2010, Polycystic ovary syndrome: A contemporary view. J Obstet Gynaecol Can, 32(5): 423–425. https://doi.org/10.1016/S1701-2163(16)34493-0

Walters KA, Gilchrist RB, Ledger WL, et al., 2018, New perspectives on the pathogenesis of PCOS: Neuroendocrine origins. Trends Endocrinol Metab, 29(12): 841–852. https://doi.org/10.1016/j.tem.2018.08.005

Lv PP, Jin M, Rao JP, et al., 2020, Role of anti-Müllerian hormone and testosterone in follicular growth: A cross-sectional study. BMC Endocr Disord, 20(1): 101. https://doi.org/10.1186/s12902-020-00569-6

Ashraf S, Nabi M, Rashid F, et al., 2019, Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: A review. Egypt J Med Hum Genet, 20(1): 25. https://doi.org/10.1186/s43042-019-0031-4

Yau TT, Ng NY, Cheung LP, et al., 2017, Polycystic ovary syndrome: A common reproductive syndrome with long-term metabolic consequences. Hong Kong Med J, 23(6): 622–634. https://doi.org/10.12809/hkmj176308

Yilmaz M, Bukan N, Ayvaz G, et al., 2005, The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod, 20(12): 3333–3340. https://doi.org/10.1093/humrep/dei258

Moller DE, Flier JS, 1988, Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans, and the polycystic ovary syndrome (Type A insulin resistance). N Engl J Med, 319(23): 1526–1529. https://doi.org/10.1056/NEJM198812083192306

Diamanti-Kandarakis E, Papavassiliou AG, 2006, Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med, 12(7): 324–332. https://doi.org/10.1016/j.molmed.2006.05.006

Burghen GA, Givens JR, Kitabchi AE, 1980, Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab, 50(1): 113–116. https://doi.org/10.1210/jcem-50-1-113

Armanini D, Boscaro M, Bordin L, et al., 2022, Controversies in the pathogenesis, diagnosis and treatment of PCOS: Focus on insulin resistance, inflammation, and hyperandrogenism. Int J Mol Sci, 23(8): 4110. https://doi.org/10.3390/ijms23084110

Willis D, Franks S, 1995, Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the Type-I insulin-like growth factor receptor. J Clin Endocrinol Metab, 80(12): 3788–3790. https://doi.org/10.1210/jcem.80.12.8530637

Azziz R, Carmina E, Dewailly D, et al., 2009, The androgen excess and PCOS society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril, 91(2): 456–488. https://doi.org/10.1016/j.fertnstert.2008.06.035

Gambineri A, Patton L, Altieri P, et al., 2012, Polycystic ovary syndrome is a risk factor for Type 2 diabetes: Results from a long-term prospective study. Diabetes, 61(9): 2369–2374. https://doi.org/10.2337/db11-1360

Bremer AA, Miller WL, 2008, The serine phosphorylation hypothesis of polycystic ovary syndrome: A unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril, 89(5): 1039–1048. https://doi.org/10.1016/j.fertnstert.2008.02.091

Siddiqui S, Mateen S, Ahmad R, et al., 2022, A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). J Assist Reprod Genet, 39(11): 2439–2473. https://doi.org/10.1007/s10815-022-02625-7

Moll GW Jr., Rosenfield RL, 1983, Plasma free testosterone in the diagnosis of adolescent polycystic ovary syndrome. J Pediatr, 102(3): 461–464. https://doi.org/10.1016/S0022-3476(83)80678-7

Van Hooff MH, Voorhorst FJ, Kaptein MB, et al., 2000, Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil Steril, 74(1): 49–58. https://doi.org/10.1016/S0015-0282(00)00584-7

Diamanti-Kandarakis E, Dunaif A, 2012, Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr Rev, 33(6): 981–1030. https://doi.org/10.1210/er.2011-1034

Zuo T, Zhu M, Xu W, 2016, Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev, 2016: 8589318. https://doi.org/10.1155/2016/8589318

Sabuncu T, Vural H, Harma M, et al., 2001, Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem, 34(5): 407–413. https://doi.org/10.1016/S0009-9120(01)00245-4

Patel S, 2018, Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol, 182: 27–36. https://doi.org/10.1016/j.jsbmb.2018.04.008

Xue Z, Li J, Feng J, et al., 2021, Research progress on the mechanism between polycystic ovary syndrome and abnormal endometrium. Front Physiol, 12: 788772. https://doi.org/10.3389/fphys.2021.788772

Yang Y, Qiao J, Li R, et al., 2011, Is interleukin-18 associated with polycystic ovary syndrome? Reprod Biol Endocrinol, 9(1): 7. https://doi.org/0.1186/1477-7827-9-7

González F, Nair KS, Daniels JK, et al., 2012, Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J Clin Endocrinol Metab, 97(8): 2836–2843. https://doi.org/10.1210/jc.2012-1259

Rosenfield RL, Ehrmann DA, 2016, The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev, 37(5): 467–520. https://doi.org/10.1210/er.2015-1104

Day F, Karaderi T, Jones MR, et al., 2018, Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet, 14(12): e1007813. https://doi.org/10.1371/journal.pgen.1007813

Escobar-Morreale HF, 2018, Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol, 14(5): 270–284. https://doi.org/10.1038/nrendo.2018.24

Aziz R, Carmina E, Chen Z, et al., 2016, Polycystic ovary syndrome. Nat Rev Dis Primers, 2(1): 16057. https://doi.org/10.1038/nrdp.2016.57

Lizneva D, Suturina L, Walker W, et al., 2016, Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril, 106(1): 6–15. https://doi.org/10.1016/j.fertnstert.2016.05.003

Meczekalski B, Pérez-Roncero GR, López-Baena MT, et al., 2020, The polycystic ovary syndrome and gynecological cancer risk. J Gynaecol Endocrinol, 36(4): 289–293. https://doi.org/10.1080/09513590.2020.1730794

Barry JA, Azizia MM, Hardiman PJ, 2014, Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update, 20(5): 748–758. https://doi.org/10.1093/humupd/dmu012

de França Neto AH, Rogatto S, Do Amorim MM, et al., 2010, Oncological repercussions of polycystic ovary syndrome. J Gynaecol Endocrinol, 26(10): 708–711. https://doi.org/10.3109/09513590.2010.490607

Parker SL, 1997, Cancer statistics, 1997. CA Cancer J Clin, 47: 5–27. https://doi.org/10.3322/canjclin.47.1.5

National Cancer Institute of Canada, 2003, Canadian Cancer Statistics. Toronto, Canada: National Cancer Institute.

Daniilidis A, Dinas K, 2009, Long term health consequences of polycystic ovarian syndrome: A review analysis. Hippokratia, 13(2): 90–92.

Hardiman P, Pillay OS, Atiomo W, 2003, Polycystic ovary syndrome and endometrial carcinoma. Lancet, 361(9371): 1810–1812. https://doi.org/10.1016/S0140-6736(03)13409-5

Pillay OC, Te Fong, LW, Crow JC, et al., 2006, The association between polycystic ovaries and endometrial cancer. Hum Reprod, 21(4): 924–929. https://doi.org/10.1093/humrep/dei420

Atiomo W, Khalid S, Parameshweran S, et al., 2009, Proteomic biomarkers for the diagnosis and risk stratification of polycystic ovary syndrome: A systematic review. BJOG, 116(2): 137–143. https://doi.org/10.1111/j.1471-0528.2008.02041.x

Gottschau M, Kjaer SK, Jensen A, et al., 2015, Risk of cancer among women with polycystic ovary syndrome: A Danish cohort study. Gynecol Oncol, 136(1): 99–103. https://doi.org/10.1016/j.ygyno.2014.11.012

Shen CC, Yang AC, Hung JH, et al., 2015, A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome. Oncologist, 20(1): 45–49. https://doi.org/10.1634/theoncologist.2014-0311

Haoula Z, Salman M, Atiomo W, 2012, Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod, 27(5): 1327–1331. https://doi.org/10.1093/humrep/des042

Fearnley EJ, Marquart L, Spurdle AB, et al., 2010, Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: An Australian case-control study. Cancer Causes Control, 21(12): 2303–2308. https://doi.org/10.1007/s10552-010-9658-7

Reid BM, Permuth JB, Sellers TA, 2017, Epidemiology of ovarian cancer: A review. Cancer Biol Med, 14(1): 9–32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084

Risch HA, 1998, Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst, 90(23): 1774–1786. https://doi.org/10.1093/jnci/90.23.1774

Hunn J, Rodriguez GC, 2012, Ovarian cancer: Etiology, risk factors, and epidemiology. Clin Obstet Gynecol, 55(1), 3–23. https://doi.org/10.1097/GRF.0b013e31824b4611

Ali AT, 2014, Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer, 24(3): 384–393. https://doi.org/10.1097/IGC.0000000000000075

Rojas K, Stuckey A, 2016, Breast cancer epidemiology and risk factors. Clin Obstet Gynecol, 59(4): 651–672. https://doi.org/10.1097/GRF.0000000000000239

Pérez-López FR, 2019, Sporadic ovarian and fallopian tube cancer in postmenopausal women. In: Postmenopausal Diseases and Disorders. Cham: Springer. p79–100. https://doi.org/10.1007/978-3-030-13936-0_5

Brinton LA, Moghissi KS, Westhoff CL, et al., 2010, Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). Fertil Steril, 94(5): 1787–1792. https://doi.org/10.1016/j.fertnstert.2009.10.012

Bray F, Ferlay J, Soerjomataram I, et al., 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6): 394–424. https://doi.org/10.3322/caac.21492

Xu H, Han Y, Lou J, et al., 2017, PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer. Oncotarget, 8(41): 69520–69526. https://doi.org/10.18632/oncotarget.17846

Cooney LG, Dokras A, 2018, Beyond fertility: Polycystic ovary syndrome and long-term health. Fertil Steril, 110(5): 794–809. https://doi.org/10.1016/j.fertnstert.2018.08.021

Terry KL, Willett WC, Rich-Edwards JW, et al., 2006, A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med, 166(22): 2484–2489. https://doi.org/10.1001/archinte.166.22.2484

LedgerWL, 2003, Non-reproductiveconsequencesofpolycystic ovary syndrome. Curr Obstet Gynecol, 13(6): 350–354. https://doi.org/10.1016/S0957-5847(03)00072-6

Mravec B, Tibensky M, 2020, Increased cancer risk in polycystic ovary syndrome: An (un) sympathetic connection? Med Hypotheses, 134: 109437. https://doi.org/10.1016/j.mehy.2019.109437

Shafiee MN, Chapman C, Barrett D, et al., 2013, Reviewing the molecular mechanisms which increase endometrial cancer (EC) risk in women with polycystic ovarian syndrome (PCOS): Time for paradigm shift? Gynecol Oncol, 131(2): 489–492. https://doi.org/10.1016/j.ygyno.2013.06.032

Arcidiacono B, Iiritano S, Nocera A, et al., 2012, Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms. Exp Diabetes Res, 2012: 789174. https://doi.org/10.1155/2012/789174

Grivennikov SI, Greten FR, Karin M, 2010, Immunity, inflammation, and cancer. Cell J, 140(6): 883–899. https://doi.org/10.1016/j.cell.2010.01.025

Zahalka AH, Arnal-Estapé A, Maryanovich M, et al., 2017, Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science, 358(6361): 321–326. https://doi.org/10.1126/science.aah5072

Hara MR, Kovacs JJ, Whalen EJ, et al., 2011, A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1. Nature, 477(7364): 349–353. https://doi.org/10.1038/nature10368

Magnon C, Hall SJ, Lin J, et al., 2013, Autonomic nerve development contributes to prostate cancer progression. Science, 341(6142): 1236361. https://doi.org/10.1126/science.1236361

Papaioannou S, Tzafettas J, 2010, Anovulation with or without PCO, hyperandrogenaemia and hyperinsulinaemia as promoters of endometrial and breast cancer. Best Pract Res Clin Obstet Gynaecol, 24(1): 19–27. https://doi.org/10.1016/j.bpobgyn.2008.11.010

Dumesic DA, Lobo RA, 2013, Cancer risk and PCOS. Steroids, 78(8): 782–785. https://doi.org/10.1016/j.steroids.2013.04.004

Yumiceba V, López-Cortés A, Pérez-Villa A, et al., 2020, Oncology and pharmacogenomics insights in polycystic ovary syndrome: An integrative analysis. Front Endocrinol (Lausanne), 11: 585130. https://doi.org/10.3389/fendo.2020.585130

Setiawan VW, Yang HP, Pike MC, et al., 2013, Type I and II endometrial cancers: Have they different risk factors? Clin Oncol, 31(20): 2607–2018. https://doi.org/10.1200%2FJCO.2012.48.2596

Samarnthai N, Hall K, Yeh IT, 2010, Molecular profiling of endometrial malignancies. Obstet Gynecol, 2010: 162363. https://doi.org/10.1155/2010/162363

Zou J, Li Y, Liao N, et al., 2022, Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis. J Ovarian Res, 15(1): 1–16. https://doi.org/10.1186/s13048-022-00962-w

Toss A, Tomasello C, Razzaboni E, et al., 2015, Hereditary ovarian cancer: Not only BRCA 1 and 2 genes. Biomed Res Int, 2015: 341723. https://doi.org/10.1155/2015/341723

Perets R, Wyant GA, Muto KW, et al., 2013, Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca; Tp53; Pten models. Cancer Cell, 24(6): 751–765. https://doi.org/10.1016/j.ccr.2013.10.013